0
0
New Delhi, May 18, 2025 – Indian biotechnology companies are making significant strides in the development of mRNA-based vaccines and therapeutics, according to scientists from the Department of Biotechnology (DBT), Ministry of Science and Technology. The announcement was made during the 14th session of the ‘Webinar Series on Biofoundry and Biomanufacturing Initiative’, held in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC).
Focus on mRNA Therapeutics
The session, centered on “Biomanufacturing for mRNA Therapeutics,” highlighted the growing importance of mRNA technologies in healthcare. Dr. Alka Sharma, Senior Adviser at DBT, emphasized that the BioE3 (Biotechnology for Economy, Environment and Employment) Policy is driving India’s vision for high-performance biomanufacturing, sustainable green growth, and global leadership in bio-based innovations.
“Several Indian biotech companies and research institutions are actively involved in developing mRNA-based vaccines and therapeutics,” Dr. Sharma said. She also pointed out key challenges facing the sector, including product delivery, stability, and dependence on imported raw materials.
BioE3 Policy: Aiming for Global Leadership
The BioE3 Policy, approved by the Union Cabinet and released by the Minister of Science and Technology, aims to position India as a global leader in bio-based innovations. The policy supports sustainable biomanufacturing in areas such as precision therapeutics, including mRNA technologies, with a focus on promoting affordable healthcare for the Indian population.
Cutting-Edge Advances and Opportunities
Dr. Varshneya Singh, Scientist at DBT, provided an overview of the mRNA therapeutics subsector, describing mRNA-based therapies as a “groundbreaking advancement in biotechnology” with the potential to address a wide range of diseases, including cancer, genetic disorders, and infectious diseases.
Dr. Raghavan Varadarajan from the Indian Institute of Science (IISc), Bangalore, discussed the latest advancements in mRNA-LNP (lipid nanoparticle) vaccine technology, highlighting its revolutionary impact on modern medicine. He detailed the workflow for mRNA vaccine design, the structural elements of mRNA, and comparative analyses of various formulation methods.
Collaborative Efforts for Future Growth
The webinar brought together experts from academia, industry, start-ups, and research organizations to discuss the latest developments and future opportunities in mRNA therapeutics and biomanufacturing.
Disclaimer: This article is based on information auto-generated from a syndicated news feed and has not been independently edited or verified by the publishing team. For more details, refer to the original source at Sakshi Post.
